Ziv-Aflibercept
Ziv-Aflibercept
Definition
A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.
Also known as AFLIBERCEPT, Aflibercept beta, AVE0005, Eylea, Vascular Endothelial Growth Factor Trap, VEGF Trap, VEGF Trap R1R2, VEGF-Trap, Zaltrap, Ziv-Aflibercept — per NCIT
Also identified as
- ATC L01XX44 per RXNORM
- ATC S01LA05 per RXNORM
- NCIT NCIT:C2682 per NCIT
- SCTID 703840003 per RXNORM
- SCTID 714627007 per RXNORM
- UNII 15C2VL427D per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Diabetic retinopathy | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Camera-type eye | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Retina | may treat a disease of this organ | DERIVED · CC BY 4.0 |
3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.